Genmab A/S (NASDAQ:GMAB) Receives $39.17 Average Price Target from Analysts

Shares of Genmab A/S (NASDAQ:GMAB) have been assigned a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $39.17.

GMAB has been the subject of several research analyst reports. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Truist Financial decreased their price target on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Sanford C. Bernstein cut Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday, April 1st. Finally, BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC increased its position in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after buying an additional 939 shares in the last quarter. Headlands Technologies LLC increased its holdings in shares of Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after acquiring an additional 1,464 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock worth $38,000 after purchasing an additional 1,070 shares during the period. Lindbrook Capital LLC lifted its holdings in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after purchasing an additional 950 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after purchasing an additional 2,285 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $20.52 on Monday. The business has a fifty day moving average of $19.75 and a 200-day moving average of $20.72. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $30.06. The firm has a market cap of $13.16 billion, a PE ratio of 11.79, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The firm had revenue of $715.00 million during the quarter, compared to analysts’ expectations of $5.17 billion. On average, analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.